Claims for Patent: 9,539,203

Summary for Patent: 9,539,203

Title:	Pharmaceutical composition comprising a Vitamin E derivative and a cell death marker
Abstract:	The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.
Inventor(s):	Cordeiro; Francesca (London, GB), Moss; Stephen (London, GB)
Assignee:	UCL BUSINESS PLC (London, GB)
Application Number:	12/809,262
Patent Claims:	1. A pharmaceutical composition, comprising: a combination of a Vitamin E derivative and a cell death marker, wherein the cell death marker is annexin V or a functional fragment or derivative thereof that binds reversibly to cellular membranes in the presence of cations. 2. The pharmaceutical composition of claim 1, wherein the Vitamin E derivative is a tocopherol or a derivative thereof. 3. The pharmaceutical composition of claim 2, wherein the tocopherol is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 4. A method of delivering a cell death marker to a posterior segment of an eye, comprising: administering the pharmaceutical composition of claim 1 to the eye. 5. The method of claim 4, wherein the Vitamin E derivative is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 6. The method of claim 4, wherein the pharmaceutical composition is formulated for topical delivery. 7. The method of claim 4, wherein the biologically or therapeutically active agent and pharmaceutical composition are delivered topically. 8. The method of claim 7, wherein the Vitamin E derivative is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 9. The method of claim 4 further comprising delivering a neuroprotectant, a growth factor, a growth factor antagonist, an antibody, an aptamer, or a steroid to the eye. 10. The pharmaceutical composition of claim 1, wherein the composition further comprises one or more additional components selected from physiological saline, bacteriostatic water, polyethoxylated castor oil, ethanol and polyol. 11. A pharmaceutical composition comprising a Vitamin E derivative; and a cell death marker, wherein the cell death marker is an annexin or functional fragment or derivative thereof that binds reversibly to cellular membranes in the presence of cations and wherein the Vitamin E derivative is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 12. The pharmaceutical composition of claim 11, wherein the annexin is annexin V. 13. The pharmaceutical composition of claim 11, wherein the composition further comprises one or more additional components selected from the physiological saline, bacteriostatic water, polyethoxylated castor oil, ethanol and polyol. 14. The pharmaceutical composition of claim 1, wherein the composition further comprises phosphatidylserine and/or phosphatidylethanolamine. 15. The method of claim 9 wherein the neuroprotectant is memantine or the antibody is selected from ranibizumab and bevacizumab.

Details for Patent 9,539,203

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-12-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2027-12-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2027-12-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2027-12-19
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2027-12-19